Indian business conglomerate the Tata group says that it has purchased a significant equity stake in Indigene Pharmaceutical, a subsidiary of USA-based drugmaker Indigene Pharma. The firm added that it has bought a 25% stake in the biopharmaceutical firm for an undisclosed amount.
In response, M Vaman Rao, chief executive of Indigene, said that the strategic alliance would enable the firm to leverage the Tata group's reputation in nurturing the growth phase of ventures, thereby strengthening the organization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze